The 36-month beta value for MBIO is also noteworthy at 2.16. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for MBIO is 1.96M, and at present, short sellers hold a 3.08% of that float. The average trading volume of MBIO on April 24, 2025 was 195.31K shares.
MBIO) stock’s latest price update
The stock price of Mustang Bio Inc (NASDAQ: MBIO) has dropped by -8.33 compared to previous close of 1.33. Despite this, the company has seen a fall of -9.05% in its stock price over the last five trading days. globenewswire.com reported 2025-03-05 that WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement as required by Nasdaq Listing Rule 5550(b)(1).
MBIO’s Market Performance
MBIO’s stock has fallen by -9.05% in the past week, with a monthly drop of -14.18% and a quarterly drop of -70.20%. The volatility ratio for the week is 8.47% while the volatility levels for the last 30 days are 9.19% for Mustang Bio Inc The simple moving average for the last 20 days is -7.57% for MBIO’s stock, with a simple moving average of -87.11% for the last 200 days.
Analysts’ Opinion of MBIO
Many brokerage firms have already submitted their reports for MBIO stocks, with BTIG Research repeating the rating for MBIO by listing it as a “Buy.” The predicted price for MBIO in the upcoming period, according to BTIG Research is $11 based on the research report published on May 18, 2021 of the previous year 2021.
B. Riley FBR, on the other hand, stated in their research note that they expect to see MBIO reach a price target of $9. The rating they have provided for MBIO stocks is “Buy” according to the report published on October 02nd, 2020.
Cantor Fitzgerald gave a rating of “Overweight” to MBIO, setting the target price at $7 in the report published on November 20th of the previous year.
MBIO Trading at -29.17% from the 50-Day Moving Average
After a stumble in the market that brought MBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.13% of loss for the given period.
Volatility was left at 9.19%, however, over the last 30 days, the volatility rate increased by 8.47%, as shares sank -13.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -57.94% lower at present.
During the last 5 trading sessions, MBIO fell by -8.99%, which changed the moving average for the period of 200-days by -94.70% in comparison to the 20-day moving average, which settled at $1.3186. In addition, Mustang Bio Inc saw -86.23% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for MBIO
The total capital return value is set at 4.92. Equity return is now at value -1191.31, with -116.47 for asset returns.
Based on Mustang Bio Inc (MBIO), the company’s capital structure generated -0.29 points at debt to capital in total, while cash flow to debt ratio is standing at -13.0. The debt to equity ratio resting at -0.23. The interest coverage ratio of the stock is -3249.0.
Currently, EBITDA for the company is -16.25 million with net debt to EBITDA at 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.68.
Conclusion
In summary, Mustang Bio Inc (MBIO) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
